Curated News
By: NewsRamp Editorial Staff
May 19, 2026

Datavault AI Licenses Tech to Wellgistics, Taking on PBMs

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Datavault AI's exclusive license with Wellgistics Health gives a competitive edge by reducing PBM intermediaries and lowering drug costs.
  • PharmacyChain tracks prescriptions from manufacturer to patient, automating processes traditionally handled by PBMs, using Datavault AI's patented tech.
  • This platform aims to lower prescription drug prices for patients by bypassing costly PBM rebate structures.
  • Did you know PBMs control complex rebate systems that inflate US drug prices; Datavault AI's tech aims to bypass them.

Impact - Why it Matters

This news matters because it targets the opaque pricing and rebate structures of pharmacy benefit managers (PBMs), which contribute to high U.S. drug costs. By licensing its AI-driven technology exclusively to Wellgistics Health for use in the PharmacyChain platform, Datavault AI aims to streamline prescription fulfillment and reduce reliance on traditional intermediaries. If successful, this could lower drug prices for patients and employers, while offering a more transparent and efficient supply chain. For investors, it highlights the growing potential of tech-driven solutions to disrupt entrenched healthcare systems.

Summary

Prescription drug prices in the United States are among the highest in the world, driven in part by complex rebate structures controlled by pharmacy benefit managers (PBMs). Datavault AI (NASDAQ: DVLT), a technology company focused on AI-driven data monetization and digital asset infrastructure, is entering this landscape through an exclusive licensing agreement with Wellgistics Health Inc. The agreement positions the company’s technology at the center of a platform designed to streamline prescription distribution and reduce reliance on traditional intermediaries.

According to the company, the agreement outlines an exclusive patent license granted to Wellgistics Health, giving the company sole access within its market segment to Datavault AI’s proprietary technologies. This exclusivity is a defining feature of the agreement, as it prevents direct competitors from utilizing the same innovations. At the center of the initiative is PharmacyChain(TM), a platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes that are traditionally routed through PBMs. By granting exclusive access, Datavault AI creates a stronger commercial incentive for adoption while also reinforcing the value of its intellectual property portfolio.

The partnership targets significant inefficiencies in the pharmaceutical supply chain, where opaque pricing and rebate structures have long frustrated patients, employers, and healthcare providers. PharmacyChain aims to bring transparency and automation to prescription fulfillment, potentially lowering costs and improving patient outcomes. For investors, this deal underscores the growing value of AI-driven solutions in healthcare logistics. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT. This move could signal a shift toward more direct and efficient drug distribution models, challenging the dominance of PBMs and reshaping the pharmaceutical landscape.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Datavault AI Licenses Tech to Wellgistics, Taking on PBMs

blockchain registration record for this content.